Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.

Freyer G, Duret A, Milano G, Chatelut E, Rebischung C, Delord JP, Merrouche Y, Lledo G, Etienne MC, Falandry C.

Anticancer Res. 2011 Jan;31(1):359-66.

PMID:
21273624
2.

Methylenetetrahydrofolate reductase gene polymorphisms and response to fluorouracil-based treatment in advanced colorectal cancer patients.

Etienne MC, Formento JL, Chazal M, Francoual M, Magné N, Formento P, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G.

Pharmacogenetics. 2004 Dec;14(12):785-92.

PMID:
15608557
3.

Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice.

Filipski E, King VM, Etienne MC, Li X, Claustrat B, Granda TG, Milano G, Hastings MH, Lévi F.

Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R844-51. Epub 2004 Jun 24.

4.

Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.

Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P.

J Natl Cancer Inst. 2004 Apr 21;96(8):636-7. No abstract available.

PMID:
15100346
5.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity.

Etienne MC, Ilc K, Formento JL, Laurent-Puig P, Formento P, Cheradame S, Fischel JL, Milano G.

Br J Cancer. 2004 Jan 26;90(2):526-34.

6.

ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.

Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, Tiffon C, Renée N, Marchetti S, Etienne MC, Milano G.

Clin Cancer Res. 2003 Oct 15;9(13):4735-42.

7.

Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.

Magné N, Fischel JL, Tiffon C, Formento P, Dubreuil A, Renée N, Formento JL, Francoual M, Ciccolini J, Etienne MC, Milano G.

Br J Cancer. 2003 Aug 4;89(3):585-92.

8.

Oxaliplatin-5-fluorouracil and ionizing radiation. Importance of the sequence and influence of p53 status.

Magné N, Fischel JL, Formento P, Etienne MC, Dubreuil A, Marcié S, Lagrange JL, Milano G.

Oncology. 2003;64(3):280-7.

PMID:
12697970
9.

Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression.

Porsin B, Formento JL, Filipski E, Etienne MC, Francoual M, Renée N, Magné N, Lévi F, Milano G.

Eur J Cancer. 2003 Apr;39(6):822-8.

PMID:
12651209
10.

Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.

Etienne MC, Leger F, Pivot X, Chatelut E, Bensadoun RJ, Guardiola E, Renée N, Magné N, Canal P, Milano G.

Ann Oncol. 2003 Apr;14(4):643-7.

PMID:
12649114
11.

Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.

Etienne MC, Chazal M, Laurent-Puig P, Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G.

J Clin Oncol. 2002 Jun 15;20(12):2832-43.

PMID:
12065560
12.

Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity.

Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, Milano G.

Br J Cancer. 2002 Apr 8;86(7):1162-8.

13.

Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.

Marchetti S, Chazal M, Dubreuil A, Fischel JL, Etienne MC, Milano G.

Br J Cancer. 2001 Aug 3;85(3):439-45.

14.

Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival.

Rosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, Pezet D, Beaune P, Laurent-Puig P, Milano G.

Int J Cancer. 2001 May 20;95(3):162-7.

15.

Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines.

Fischel JL, Rostagno P, Formento P, Dubreuil A, Etienne MC, Milano G.

Br J Cancer. 2001 Feb;84(4):579-85.

16.

P53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up.

Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G.

Ann Oncol. 2000 Apr;11(4):393-7.

PMID:
10847456
17.

Known variant DPYD alleles do not explain DPD deficiency in cancer patients.

Collie-Duguid ES, Etienne MC, Milano G, McLeod HL.

Pharmacogenetics. 2000 Apr;10(3):217-23.

PMID:
10803677
18.

Cloning and initial characterization of the human DPYD gene promoter.

Collie-Duguid ES, Johnston SJ, Powrie RH, Milano G, Etienne MC, Rochat B, Watson GC, McLeod HL.

Biochem Biophys Res Commun. 2000 Apr 29;271(1):28-35.

PMID:
10777676
19.

A multivariate analysis for predicting cisplatin-induced delayed emesis.

Pivot X, Marghali N, Etienne MC, Bensadoun RJ, Thyss A, Otto J, François E, Renée N, Lagrange JL, Schneider M, Milano G.

Oncol Rep. 2000 May-Jun;7(3):515-9.

PMID:
10767361
20.

Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients.

Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G.

Br J Cancer. 2000 Jan;82(1):171-7.

21.
22.

A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracil.

Etienne MC, Pivot X, Formento JL, Bensadoun RJ, Formento P, Dassonville O, Francoual M, Poissonnet G, Fontana X, Schneider M, Demard F, Milano G.

Br J Cancer. 1999 Apr;79(11-12):1864-9.

23.

Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.

Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renée N.

Br J Cancer. 1999 Feb;79(3-4):627-30.

24.

Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.

Pavillard V, Formento P, Rostagno P, Formento JL, Fischel JL, Francoual M, Etienne MC, Milano G.

Biochem Pharmacol. 1998 Nov 15;56(10):1315-22.

PMID:
9825730
25.
26.

Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome.

Etienne MC, Formento JL, Lebrun-Frenay C, Gioanni J, Chatel M, Paquis P, Bernard C, Courdi A, Bensadoun RJ, Pignol JP, Francoual M, Grellier P, Frenay M, Milano G.

Clin Cancer Res. 1998 Oct;4(10):2383-90.

27.

Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study.

Bensadoun RJ, Etienne MC, Dassonville O, Chauvel P, Pivot X, Marcy PY, Prevost B, Coche-Dequeant B, Bourdin S, Vallicioni J, Poissonnet G, Courdi A, Teissier E, Lagrange JL, Thyss A, Santini J, Demard F, Schneider M, Milano G.

Int J Radiat Oncol Biol Phys. 1998 Sep 1;42(2):237-45.

PMID:
9788400
28.

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.

Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Rivière A, Perrocheau G, Etienne MC, Milano G.

Clin Cancer Res. 1998 Sep;4(9):2039-45.

29.

Thymidylate synthase expression and activity: relation to S-phase parameters and 5-fluorouracil sensitivity.

Mirjolet JF, Barberi-Heyob M, Merlin JL, Marchal S, Etienne MC, Milano G, Bey P.

Br J Cancer. 1998 Jul;78(1):62-8.

30.

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

Etienne MC, Chatelut E, Pivot X, Lavit M, Pujol A, Canal P, Milano G.

Eur J Cancer. 1998 Jan;34(1):92-7.

PMID:
9624244
31.

Cisplatin nephrotoxicity: a multivariate analysis of potential predisposing factors.

Lagrange JL, Médecin B, Etienne MC, Pivot X, Cassuto-Viguier E, Renée N, Thyss A, Ferrero JM, Otto J, François E, Milano G.

Pharmacotherapy. 1997 Nov-Dec;17(6):1246-53.

PMID:
9399607
32.

Tumoral-reduced folates and clinical resistance to fluorouracil-based treatment in head and neck cancer patients.

Chéradame S, Etienne MC, Formento P, Schneider M, Dassonville O, Demard F, Milano G.

J Clin Oncol. 1997 Jul;15(7):2604-10.

PMID:
9215831
33.

Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.

Fischel JL, Formento P, Etienne MC, Spector T, Renée N, Milano G.

Biochem Pharmacol. 1997 Jun 1;53(11):1703-9.

PMID:
9264323
34.

Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.

Chéradame S, Etienne MC, Chazal M, Guillot T, Fischel JL, Formento P, Milano G.

Eur J Cancer. 1997 May;33(6):950-9.

PMID:
9291820
35.

Decreased folylpolyglutamate synthetase activity in tumors resistant to fluorouracil-folinic acid treatment: clinical data.

Chazal M, Cheradame S, Formento JL, Francoual M, Formento P, Etienne MC, François E, Richelme H, Mousseau M, Letoublon C, Pezet D, Cure H, Seitz JF, Milano G.

Clin Cancer Res. 1997 Apr;3(4):553-7.

36.

Tumoral platinum concentrations in patients treated with repeated low-dose cisplatin as a radiosensitizer.

Lagrange JL, Bondiau PY, Tessier E, Chauvel P, Renée N, Etienne MC, Milano G.

Int J Cancer. 1996 Nov 15;68(4):452-6.

37.

Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: theory and limits.

Milano G, Etienne MC.

Ther Drug Monit. 1996 Aug;18(4):335-40. Review.

PMID:
8857547
38.

Age-related difference in tamoxifen disposition.

Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, François E, Namer M, Ferrero JM, Milano G.

Clin Pharmacol Ther. 1996 Apr;59(4):401-10.

PMID:
8612384
39.

Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver.

Chazal M, Etienne MC, Renée N, Bourgeon A, Richelme H, Milano G.

Clin Cancer Res. 1996 Mar;2(3):507-10.

40.

Critical factors for optimizing the 5-fluorouracil-folinic acid association in cancer chemotherapy.

Etienne MC, Guillot T, Milano G.

Ann Oncol. 1996 Mar;7(3):283-9. Review.

PMID:
8740793
41.

Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.

Beuzeboc P, Pierga JY, Stoppa-Lyonnet D, Etienne MC, Milano G, Pouillart P.

Eur J Cancer. 1996 Feb;32A(2):369-70. No abstract available.

PMID:
8664058
42.
43.

Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase.

Haaz MC, Fischel JL, Formento P, Renée N, Etienne MC, Milano G.

Cancer Chemother Pharmacol. 1996;38(1):52-8.

PMID:
8603452
44.

Portable pumps in cancer chemotherapy: how to deal with marked fluctuations in 5-fluorouracil blood concentrations.

Etienne MC, Lagrange JL, Francois E, Renée N, Bajard F, Milano G.

Eur J Cancer. 1995 Dec;31A(13-14):2414-5. No abstract available.

PMID:
8652279
45.

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.

Stéphan F, Etienne MC, Wallays C, Milano G, Clergue F.

Am J Med. 1995 Dec;99(6):685-8. No abstract available.

PMID:
7503095
46.

Correlation between catalytic activity and protein content for the polymorphically expressed dihydropyrimidine dehydrogenase in human lymphocytes.

Fernandez-Salguero P, Gonzalez FJ, Etienne MC, Milano G, Kimura S.

Biochem Pharmacol. 1995 Sep 28;50(7):1015-20.

PMID:
7575656
47.

Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation.

Fischel JL, Etienne MC, Spector T, Formento P, Renée N, Milano G.

Clin Cancer Res. 1995 Sep;1(9):991-6.

48.

[Population study of dihydropyrimidine dehydrogenase in cancer patients].

Etienne MC, Milano G, Renée N, Lagrange JL, Dassonville O, Thyss A, Schneider M, François E, Fleming R, Demard F.

Bull Cancer. 1995 Sep;82(9):705-10. French.

PMID:
8535028
49.

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

Etienne MC, Chéradame S, Fischel JL, Formento P, Dassonville O, Renée N, Schneider M, Thyss A, Demard F, Milano G.

J Clin Oncol. 1995 Jul;13(7):1663-70.

PMID:
7602356
50.

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.

Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F.

J Clin Oncol. 1995 Jul;13(7):1656-62.

PMID:
7602355

Supplemental Content

Loading ...
Support Center